Newsroom
Sorted by: Latest
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 23.10.2026 FTFX IE00BD5HBQ97 68,116.00 USD 1,958,424.63 28.751 ...
-
Sierra Bancorp Reports Record Quarterly Income
PORTERVILLE, Calif.--(BUSINESS WIRE)--Sierra Bancorp Reports Record Quarterly Income...
-
Town Lane Raises $1.9 Billion for Second Real Estate Investment Fund
NEW YORK--(BUSINESS WIRE)--Town Lane Raises $1.9 Billion for Second Real Estate Investment Fund...
-
Object First Earns Dual Honors for Innovation in Data Security and Ransomware Protection
DENVER--(BUSINESS WIRE)--Object First, the ransomware-proof on-premises backup storage company, today announced that it has received two prestigious cybersecurity awards celebrating its innovation and commitment to protecting organizations against ransomware attacks. The company was named the winner in the “Data Security” category of Cyber Defense Magazine’s 2026 Top InfoSec Innovators Awards and was voted “Ransomware Protection and Recovery Company of the Year” in the 18th annual Computing Sec...
-
o9 Solutions Named a Leader in Analyst Evaluation of Supply Chain Platforms, Q3 2026
DALLAS--(BUSINESS WIRE)--o9 Solutions, a leading software company that is powering enterprise planning and decisioning models across 30-plus industry verticals with its groundbreaking, AI-powered Digital Brain platform, today announced that it has been named a Leader in The Forrester Wave™: Supply Chain Platforms, Q3 2026. o9 received the highest possible score in nine evaluation criteria, including synchronization of master data, supply network optimization, architecture, exploitation of langu...
-
VantageScore CreditGauge™ September 2026: Overall Balances Hold Steady as Consumer Credit Remains Stable
SAN FRANCISCO--(BUSINESS WIRE)--In September 2026, consumer credit remained resilient despite early-stage payment pressure, according to the latest edition of CreditGauge™ from VantageScore. Balances were stable, and credit card utilization remained below 2026 levels. The average VantageScore 4.0 credit score remained at 701, continuing a trend of steady consumer credit scores over the last year. “Consumers have been able to manage their debt effectively and responsibly, as evidenced in strong...
-
Acelot to Present on TDP-43 Targeting in ALS at 2026 NEALS Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced that Acelot CMO & CDO Mark Forman, MD, PhD, will present preclinical data from the company’s TDP-43 program at the upcoming 2026 Annual Network of Excellence for ALS (NEALS) meeting, taking place October 27-30 in Clearwater, FL and virtually. Additionally, Acelot CEO Katie Planey, PhD, MBA, will participat...
-
The LYCRA Company to Showcase Performance Innovations Across Wovens and Knits at Functional Fabric Fair in Portland
WILMINGTON, Del.--(BUSINESS WIRE)--The LYCRA Company to Showcase Performance Innovations Across Wovens and Knits at Functional Fabric Fair in Portland...
-
Mubadala Capital Announces Strategic Investment from Apollo
ABU DHABI, United Arab Emirates & NEW YORK--(BUSINESS WIRE)--Mubadala Capital, the alternative asset management arm of Mubadala Investment Company, today announced a strategic investment from Apollo (NYSE: APO) to support its next phase of growth. Building on their existing relationship, Apollo will take a minority equity stake in Mubadala Capital and commit capital across its various investment strategies, working alongside Mubadala Capital as it continues scaling a world-class alternative ass...
-
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data for IAM1363, a selective and brain-penetrant HER2 tyrosine kinase inhibitor (TKI), from its ongoing Phase 1/1b clinical trial. The data, which showed durable anti-tumor activity, intracranial responses and a favorable tolerability profile in heavily pretreated participants...